Book a Meeting

Anti-CD2 Antibody, Non-Fucosylated (BioBet-108ZP) (CAT#: BioBet-108ZP) Datasheet

Target
CD2
Isotype
IgG1, κ
Description
Anti-CD2 Antibody, Non-Fucosylated (BioBet-108ZP) is a humanized monoclonal IgG1, κ antibody against CD2. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Psoriasis
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD2 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD2
Full Name
CD2 Molecule
Background
CD2 (CD2 Molecule) is a Protein Coding gene.
Diseases associated with CD2 include Penis Squamous Cell Carcinoma and Immune Defect Due To Absence Of Thymus.
Among its related pathways are PEDF Induced Signaling and Akt Signaling.
Gene Ontology (GO) annotations related to this gene include protein homodimerization activity and receptor activity.
Alternative Names
Siplizumab; 288392-69-8; MEDI-507; CD2; CD2 molecule; CD2 antigen (p50), sheep red blood cell receptor, SRBC; T-cell surface antigen CD2; LFA-3 receptor; rosette receptor; erythrocyte receptor; lymphocyte-function antigen-2; T-cell surface antigen T11/Leu-5;
Gene ID
UniProt ID
Cellular Localization
Plasma membrane
Involvement in Disease
Diseases associated with CD2 include Mastocytosis, Cutaneous and Mastocytosis.
Related Pathways
Its related pathways are Cell surface interactions at the vascular wall and PEDF Induced Signaling.
Function
CD2 interacts with lymphocyte function-related antigens CD58 (LFA-3) and CD48/BCM1 to mediate adhesion between T cells and other cell types. CD2 is involved in the triggering of t cells, and the cytoplasmic domain is involved in signal transduction.
Post-translational modifications
1.Glycosylation at Asn89, Asn141, and Asn150 2.Ubiquitination at Lys264 and Lys310 3.Modification sites at PhosphoSitePlus 4.Glycosylation from GlyConnect
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1, κ
Antibody Clone
BioBet-108ZP
Host
Humanized
Species Reactivity
Human
Description
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CD2. Siplizumab (MEDI-507) is a novel monoclonal antibody with a human IgG1, kappa directed to CD2. The agent has shown potent immunomodulatory effects, selectively suppressing the function of T and NK cells, and is currently being tested as a possible treatment for psoriasis and in the prevention of graft-versus-host disease.
Antibody Indication
Psoriasis

Psoriasis

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.